AzaSite® inhibits staphylococcus aureus and coagulase-negative staphylococcus biofilm formation in vitro

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 6, 2010, Pages 557-562

  Wu, Eric C ^a   Kowalski, Regis P ^a   Romanowski, Eric G ^a   Mah, Francis S ^a   Gordon, Y Jerold ^a   Shanks, Robert M Q ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZASITE; AZITHROMYCIN; BENZALKONIUM CHLORIDE; CRYSTAL VIOLET; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIOFILM; BLEPHARITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DILUTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; IN VITRO STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECTROPHOTOMETER; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BENZALKONIUM COMPOUNDS; BIOFILMS; COAGULASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; SPECTROPHOTOMETRY; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 78649710959     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0097     Document Type: Article

References (29)

1. Smith, R.E., and Flowers, C.W., Jr. Chronic blepharitis: a review. CLAO J. 21:200-207, 1995.
2. Smolin, G., and Okumoto, M. Staphylococcal blepharitis. Arch. Ophthalmol. 95:812-816, 1977.
3. Carter, S.R. Eyelid disorders: diagnosis and management. Am. Fam. Physician 57:2695-2702, 1998.
4. Jackson, W.B. Blepharitis: current strategies for diagnosis and management. Can. J. Ophthalmol. 43:170-179, 2008.
5. Behlau, I., and Gilmore, M.S. Microbial biofilms in ophthalmology and infectious disease. Arch. Ophthalmol. 126: 1572-1581, 2008.
6. Elder, M.J., Stapleton, F., Evans, E., et al. Biofilm-related infections in ophthalmology. Eye (Lond.) 9 (Pt 1):102-109, 1995.
7. Zegans, M.E., Shanks, R.M., and O'Toole, G.A. Bacterial biofilms and ocular infections. Ocul. Surf. 3:73-80, 2005.
8. Darouiche, R.O. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429, 2004.
9. Trautner, B.W., and Darouiche, R.O. Catheter-associated infections: pathogenesis affects prevention. Arch. Intern. Med. 164:842-850, 2004.
10. Donlan, R.M. Biofilms and device-associated infections. Emerg. Infect. Dis. 7:277-281, 2001.
11. Sugita, J., Yokoi, N., Fullwood, N.J., et al. The detection of bacteria and bacterial biofilms in punctal plug holes. Cornea 20:362-365, 2001.
12. Yokoi, N., Okada, K., Sugita, J., et al. Acute conjunctivitis associated with biofilm formation on a punctal plug. Jpn. J. Ophthalmol. 44:559-560, 2000.
13. Zegans, M.E., Becker, H.I., Budzik, J., et al. The role of bacterial biofilms in ocular infections. DNA Cell Biol. 21:415-420, 2002.
14. Aslam, S. Effect of antibacterials on biofilms. Am. J. Infect Control 36:S175.e9-e11, 2008.
15. O'Gara, J.P., and Humphreys, H. Staphylococcus epidermidis biofilms: importance and implications. J. Med. Microbiol. 50:582-587, 2001.
16. Otto, M. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228, 2008.
17. Gillis, R.J., and Iglewski, B.H. Azithromycin retards Pseu-domonas aeruginosa biofilm formation. J. Clin. Microbiol. 42:5842-5845, 2004.
18. Abelson, M.B., Heller, W., Shapiro, A.M., et al. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am. J. Ophthalmol. 145:959-965, 2008.
19. Luchs, J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv. Ther. 25:858-870, 2008.
20. Friedlaender, M.H., and Protzko, E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin. Ophthalmol. 1:3-10, 2007.
21. Tamura, A., Ara, T., Imamura, Y., et al. The effects of antibiotics on in vitro biofilm model of periodontal disease. Eur. J. Med. Res. 13:439-445, 2008.
22. Starner, T.D., Shrout, J.D., Parsek, M.R., et al. Subinhibitory concentrations of azithromycin decrease nontypeable Haemo-philus influenzae biofilm formation and diminish established biofilms. Antimicrob. Agents Chemother. 52:137-145, 2008.
23. Ichimiya, T., Takeoka, K., Hiramatsu, K., et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 42:186-191, 1996.
24. Shanks, R.M., Sargent, J.L., Martinez, R.M., et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol. Dial. Transplant. 21:2247-2255, 2006.
25. Braga, P.C., and Piatti, G. Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells. Chemotherapy 39:432-437, 1993.
26. Moneib, N.A., Shibl, A.M., el-Said, M.A., et al. Macrolides induced suppression of virulence factors produced by Staphylococcus aureus. J. Chemother. 5:289-292, 1993.
27. Yanagihara, K., Morinaga, Y., Nakamura, S., et al. Sub-inhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J. Antimicrob. Chemother. 61:647-650, 2008.
28. Hoffman, L.R., D'Argenio, D.A., MacCoss, M.J., et al. Ami-noglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175, 2005.
29. Nucleo, E., Steffanoni, L., Fugazza, G., et al. Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii. BMC Microbiol. 9:270, 2009.